461 Studies Now Enrolling
A Multicenter, Open-label, Pilot Study of TAK-935 in patients with 15q duplication syndrom or CDKL5 deficiency disorder.
A clinical trial for children with 15Q duplication syndrome or CDKL5 deficiency disorder to help control seizures.
| Sponsor: | Ovid Therapeutics, Inc. |
| Enrolling: | Male and Female Patients |
| Study Length: | 22 Weeks |
| Clinic Visits: | 8 |
| IRB Number: | AAAS1026 |
| U.S. Govt. ID: | NCT03694275 |
| Contact: | Joanne Carroll: 212-305-5508 / jc688@cumc.columbia.edu |
Additional Study Information:
The purpose of this research is to determine whether a new investigational drug called TAK-935 is safe and whether it may help treat epilepsy in children with 15q duplication syndrome or CDKL5 deficiency disorder.
This study is closed
Do You Qualify?
| Has your child been diagnosed with 15q duplication syndrome, or CDKL5 deficiency disorder? | Yes | No |
| Has your child had 3 or more seizures within the last 3 months? | Yes | No |
| Have there been any anti-epileptic medication changes within the last 4 weeks? | Yes | No |
| Does your child weigh 22 lbs or more? | Yes | No |